Register Today for the September 23 Medicare 101 Webinar

Next week, the IMF Advocacy team will host the webinar Medicare 101, an important introduction to Medicare that will cover a range of topics including how to enroll, the different parts of Medicare, and various coverage options. The discussion and Q&A session will be led by Dr. Gretchen Jacobson, Associate Director, Program on Medicare Policy with the Kaiser Family Foundation. The webinar will be held on Tuesday, September 23rd at 7 pm ET/ 4 pm PT.
Source: International Myeloma Foundation - Category: Hematology Source Type: news

Related Links:

Although the BELLINI trial was put on partial hold, the trial was allowed to continue for patients for whom the addition of venetoclax showed benefit. New data now identify this subgroup.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
ConclusionsInfection-related HPS must be more common than reported. The geographical environment can influence the triggering infections (in our environment, Leishmania should be considered).ResumenIntroducciónEl síndrome hemofagocítico (SHF) es un trastorno inmunológico grave caracterizado por una inflamación descontrolada con fracaso multiorgánico. Puede estar desencadenado por infecciones víricas, bacterianas, fúngicas o parasitarias. Se describe nuestra experiencia de SHF asociado a infecciones y se estima su incidencia local.Material y métodoEstudio retros...
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research
Prognostic value of N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) was analyzed in patients with multiple myeloma complicated by dialysisdependent renal failure. The prospective study included 20 patients with newly diagnosed multiple myeloma. The concentrations of NT-proBNP were measured before antimyeloma chemotherapy. The median age of the patients was 67 (63-76) years. The median glomerular filtration rate was 4 (4, 5) ml/min/1.73 m2. For overall survival, the area under ROC curve was 0.75 and the cut-off point was 7000 pg/ml. At median follow-up of 17.3 months, the overall survival wa...
Source: Bulletin of Experimental Biology and Medicine - Category: Biology Source Type: research
ConclusionOur study showed with long follow-up, equivalent TFS after ASCT in AA and non-AA patients yet improved OS. Post relapse survival is improved in AA patients suggesting a better response to salvage therapy.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 June 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Praveen Ramakrishnan Geethakumari, John Markantonis, Jennifer Lobo Shah, Abdullah Alsuwaidan, Imran Shahab, Weina Chen, Jesse Manuel Jaso
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 1 April 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Patrizia Mondello, Cristian Di Mirto, Salvatore Cuzzocrea, Carmela Arrigo, Michael Mian, Vincenzo PitiniAbstractBackgroundDespite the important progress in the research of myeloproliferative neoplasms (MPN), treatment options are still limited. Currently, a cytoreductive approach is the backbone treatment, with hydroxyurea (HU) being the most important agent. However, this drug is not always well-tolerated and has been questionably linked to a potential leukemogenic effect. A valid alternative is interferon alfa (IFN-&al...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: November 2019Source: Materials Science and Engineering: C, Volume 104Author(s): Stefania R. Cicco, Danilo Vona, Gabriella Leone, Elvira De Giglio, Maria A. Bonifacio, Stefania Cometa, Saverio Fiore, Fabio Palumbo, Roberta Ragni, Gianluca M. FarinolaAbstractBisphosphonates are a class of drugs widely used in the clinical treatment of disorders of bone metabolism, such as osteoporosis, fibrous dysplasia, myeloma and bone metastases. Because of the negative side effects caused by oral administration of bisphosphonates, various silica mesoporous materials have been investigated for a confined and controlled r...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
Condition:   Multiple Myeloma Interventions:   Drug: Daratumumab SC in combination with Lenalidomide;   Drug: Lenalidomide PO (25mg);   Drug: Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression Sponsor:   University Hospital, Lille Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Interventions:   Biological: Descartes-11;   Drug: Fludarabine;   Drug: Cyclophosphamide Sponsor:   Cartesian Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Interventions:   Drug: Daratumumab SC in combination with Lenalidomide;   Drug: Lenalidomide PO (25mg);   Drug: Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression Sponsor:   University Hospital, Lille Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Hematology | Medicare | Myeloma